Cartiva Receives Most Promising New Product Award

Cartiva Inc., a developer of innovative products for treating cartilage damage and osteoarthritis, has announced the company’s Cartiva Synthetic Cartilage Implant (SCI) won Most Promising New Product Award at the 24th annual 2017 Phoenix Medical Device CEO Conference near Silicon Valley. Chosen by global leaders in the medical device and diagnostic industry, the award recognized Cartiva SCI as the most promising new product of 2017.
 
“We are humbled to receive this award based on votes from CEOs who are responsible for many of the health care industry’s most innovative and beneficial technologies,” said Tim Patrick, president and CEO of Cartiva. “Backed by Level 1 clinical evidence, Cartiva SCI is a proven, elegant, durable solution to debilitating, arthritic joint problems afflicting millions of adults.”
 
The Phoenix Awards are selected by industry CEOs and presented for outstanding achievement in the medical device and diagnostic industry to individuals and companies. Past recipients of the Most Promising New Product Award include Neotract (UroLift System for benign prostatic hyperplasia), NeuroPace (epilepsy therapy), Johnson and Johnson (cardiac stent, drug eluting stent), Guidant (implantable defibrillator), St. Jude Medical (Nanostim), Acclarent (balloon sinuplasty), Neuronetics (NeuroStar TMS Therapy System), CardioMEMS (wireless heart failure management system), and Concentric Medical (clot removal device for stroke.)
 
Cartiva SCI is a biocompatible polymer implant designed with physical properties similar to articular cartilage. Damaged cartilage is replaced with a small Cartiva SCI implant that provides a compressible, durable, low-friction surface.
 
Cartiva SCI received Food and Drug Administration (FDA) premarket approval in July 2016—the first and only synthetic cartilage device approved by FDA—for the treatment of painful arthritis at the base of the great toe, the most common arthritic condition in the foot. Cartiva SCI is offered by more than 1,000 U.S. foot and ankle surgeons and in Europe and Canada. It is being studied in other indications including first carpometacarpal (CMC) joint osteoarthritis at the base of the thumb.